 |
Locate Information on New Drugs Coming on the Market for a Particular Indication?
TOPIC: In this example, using International Pharmaceutical Abstracts (File 74), you want to find information on new drugs that might come on the market for rheumatoid arthritis. IPA provides information on all phases of the development and use of drugs worldwide.
COMMAND SUMMARY
BEGIN 74
SELECT RHEUMATOID()ARTHRITIS
SELECT S1 AND NEW()DRUG?
SELECT S2/2005:2006
TYPE S3/6/1-4
TYPE S3/9/1
HOW TO...
1. BEGIN 74, a database containing information about phases of drug development worldwide.
2. SELECT the disease name.
3. Narrow the search to “new drugs” and to the current year(s). |
?b 74
File 74:Int.Pharm.Abs 1970-2006/Jul B1
(c) 2006 The Thomson Corporation
Set Items Description
--- ----- -----------
?SELECT RHEUMATOID()ARTHRITIS
2638 RHEUMATOID
3891 ARTHRITIS
S1 2540 RHEUMATOID()ARTHRITIS
?SELECT S1 AND NEW()DRUG?
2540 S1
41197 NEW
294114 DRUG?
4103 NEW(W)DRUG?
S2 54 S1 AND NEW()DRUG?
?S S2/2005:2006
54 S2
26844 PY=2005 : PY=2006
S3 6 S2/2005:2006 |
4. TYPE a few records for relevance using Format 6. |
?T S3/6/1-4
3/6/1
00425705 43-08685
ABATACEPT (<IT>ORENCIA</IT>) FOR RHEUMATOID ARTHRITIS
Publication Year: 2006
3/6/2
00421444 43-04424
USING EPIDEMIOLOGY AND ARCHAEOLOGY TO UNEARTH NEW DRUG TARGETS FOR RHEUMATOID ARTHRITIS THERAPY
Publication Year: 2006
3/6/3
00404003 42-09469
EFFICACY, TOLERABILITY AND COST EFFECTIVENESS OF DISEASE-MODIFYING
ANTIRHEUMATIC DRUGS AND BIOLOGIC AGENTS IN RHEUMATOID ARTHRITIS
Publication Year: 2005
3/6/4
00402923 42-08388
ADOPTION OF CELECOXIB AND ROFECOXIB: A NATIONWIDE DATABASE STUDY
Publication Year: 2005 |
5. TYPE a desired record(s) in Format 9 to see the complete record. |
?T S3/9/1
3/9/1
DIALOG(R)File 74:Int.Pharm.Abs
(c) 2006 The Thomson Corporation. All rts. reserv.
00425705 43-08685
ABATACEPT (<IT>ORENCIA</IT>) FOR RHEUMATOID ARTHRITIS
Anonymous Medical Letter on Drugs and Therapeutics (USA), V48, (1229), p17-18, 2006
CODEN: MELEAP ISSN: 0025-732X LANGUAGE: English RECORD TYPE: Abstract
An overview of a novel drug, abatacept (Orencia) approved for the treatment of rheumatoid arthritis is presented, including mechanism of action, pharmacokinetics, clinical efficacy, and adverse effects. (9 references)
CAS REGISTRY NUMBERS: 332348-12-6 (Abatacept)
CHEMICAL/BRAND NAMES: Orencia
DESCRIPTORS: Mechanism of action -- abatacept; Pharmacodynamics --
abatacept; Pharmacokinetics -- abatacept; Blood levels -- abatacept; Excretion -- abatacept; Toxicity -- abatacept; Dosage -- abatacept; Arthritis -- abatacept; Half life -- abatacept; Costs -- abatacept; Drugs -- new ; Drugs -- approvals; Food and Drug Administration (U.S.) -- approvals
SECTION HEADINGS: Pharmacology (11); Toxicity (04); Drug evaluations (06); Drug metabolism & body distribution (15) |
RELATED HOW DO I...? SOLUTIONS
NEED HELP?
Contact the Dialog Knowledge Center
Within North America 1 800 3 DIALOG (334 2564)
Outside North America 00 800 33 DIALOG (33 34 2564)
Web Form www.dialog.com/contacts/webform
|
You are viewing the
Click below to view the
 |
